Difference between revisions of "Profiles"

From QIBA Wiki
Jump to navigation Jump to search
 
(34 intermediate revisions by 3 users not shown)
Line 4: Line 4:
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
 
Profiles '''[[How to use QIBA Profiles|may be of use]]''' at any Stage.
  
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Technically Confirmed Profiles===
+
===[[QIBA_Profile_Stages#Stage_3:_Technically_Confirmed|Stage 3]]: Clinically Feasible (formerly Technically Confirmed) Profiles===
  
* [[Media:QIBA_CTVol_TumorVolumeChangeProfile_TechConfirmed-20180622a.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2018-06-22]]
 
:* Conformance Checklists (refer to Appendix C in the Profile document - pg 42)
 
:* Assessment Procedures (refer to Section 4 in the Profile document - pg 30)
 
  
* [[Media:QIBA_FDG-PET_Profile_v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
+
*[[Media:Supplement QIBA AmyloidPET 3Jun2022 TechnicallyConfirmed.pdf| PET Amyloid 2022-06-03]]
:* [[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
 
  
* [[Media:QIBA_CT_Vol_SmallLungNoduleAssessmentInCTScreening_2018.11.18-clean-3.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
+
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]]
  
 +
* [[Media:QIBA CT Vol SmallLungNoduleAssessmentInCTScreening 2018.11.18-clean-4.pdf|CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening 2018-11-18]]
 +
 +
* [[Media:QIBACTVol TumorVolumeChange(2022)-20220721.pdf|CT Tumor Volume Change for Advanced Disease (CTV-AD) 2022-07-21 Streamlined Profile]]
 +
:* 32 pages including Conformance Checklists
 +
 +
* [[Media:QIBA FDG-PET Profile v113.pdf|FDG-PET/CT for Response to Cancer Therapy 2016-11-18]]
 +
:*[[Media:UPICT Oncologic FDG-PETCTProtocol Dec-2014a.pdf|UPICT Protocol - Oncology FDG-PET CT v2.0 2014-12]]
  
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
 
===[[QIBA_Profile_Stages#Stage_2:_Consensus|Stage 2]]: Consensus Profiles===
  
*[[Media:QIBA_CT_Lung_Density_Profile_090420-clean.pdf | QIBA CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
+
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]  
+
:*[[Media:QIBA CTA Field Test Checklist.xlsx| CTA Atherosclerosis Checklist 2020-05-28]]
  
*[[Media:QIBA_DSC-MRI_Stage2-Consensus_Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
+
*[[Media:QIBA CT Lung Density Profile 090420-clean.pdf| CT Lung Density Profile_09.04.2020, clean version]] (Contains Conformance Checklist, Appendix B) 2020-10-23
 +
:*[[Media:QIBA CT Lung Density Protocols-Appendix E.xlsx|Appendix E:CT Lung Density Protocols 2019-06-26]]
  
*[[Media:QIBA_DWIProfile_Consensus_Dec2019_Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
+
*[[Media:DCE-MRI Quantification Profile v1.0.pdf| MR DCE Quantification v1.0 2012-08-08]]
  
*[[Media:QIBA_AmyloidPET_20June2018_consensus.pdf | PET F-18 for Amyloid 2018-06-20]]  
+
*[[Media:QIBA DWIProfile Consensus Dec2019 Final.pdf| MR Diffusion-Weighted Imaging (DWI) 2019-12-20]]
  
*[[Media:MRE-QIBA_Profile-2019-06-06-CONSENSUS-maintenance.pdf | MR Elastography of the Liver 2019-06-06]]  
+
*[[Media:QIBA DSC-MRI Stage2-Consensus Profile.pdf| MR Dynamic Contrast Susceptibility (DSC) 2020-10-22]]
  
*[[Media:001.QIBA_SPECT_Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf | SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
+
*[[Media:QIBA Profile MSK-Cartilage-Stage2 Profile.pdf| MR MSK cartilage for joint disease 2021-09-25]]
  
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf | SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
+
*[[Media:001.QIBA SPECT Ioflupane Profile.v1.1 post-public comments.clean copy.2017 06 26.pdf| SPECT Ioflupane for Neurodegenerative Disease v1.1, 2017-06-26]]
  
 +
*[[Media:002.QIBA SPECT Ioflupane Profile v2.0.2019 10 15.pdf| SPECT Ioflupane for Neurodegenerative Disease v2.0, 2019-10-15]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
 
:*[[Media:002.QIBA SPECT Profile Checklist Extract.2016 10 31.docx|Checklist - SPECT Profile Conformance]]
  
*[[Media:DCE-MRI Quantification Profile v1.0.pdf|MR DCE Quantification v1.0 2012-08-08]]
+
*[[Media:QIBA SPECT 99mTC Profile 10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 
 
*[[Media:QIBA_CTA_Profile_as_of_2020-Mar-10.pdf| CTA Atherosclerosis 2020-03-10]]
 
 
 
*[[Media:QIBA_SPECT_99mTC_Profile_10.21.19.pdf|SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21]]
 
  
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles===
+
*[[Media:QIBA US SWS Profile 04.25.2022-clean version.pdf|US Shear Wave Speed for Liver Fibrosis-2022-04-25]] ('''closed''' on May 3, 2022)
 +
:*[[Media:SWS Checklists-Appendix E-04.25.2022.xlsx|Appendix E: SWS Checklists]] (updated April 25, 2022)
  
'''Please submit comments using the '''[http://tinyurl.com/QIBA-Public-Comment-Form '''online form''']'''
+
===[[QIBA_Profile_Stages#Stage_1:_Public_Comment|Stage 1]]: Public Comment Profiles ===
  
*[[Media:QIBA_Profile_MSK-Cartilage-Stage1_Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] (<font color=##00cc00>'''Open for comment: June 26, 2020 - Thursday, October 29, 2020 [extended]'''</font>)
+
'''Please submit comments using the '''[https://forms.gle/bPzUAuLKJnHYGbVS7 '''online form''']
  
*[[Media:QIBA_US_SWS_Profile_10.21.19.pdf|US Shear Wave Speed for Liver Fibrosis 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA DCE-MRI Profile-Stage 1-Public Comment.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2020-10-12]] ('''closed''' on March 10, 2021)
  
:*[[Media:SWS Checklists-Appendix E.xlsx|Appendix E: SWS Checklists, 2019-10-21]] ('''closed''' on December 18, 2019)
+
*[[Media:QIBA Profile MSK-Cartilage-Stage1 Profile.pdf|MR MSK cartilage for joint disease 2020-05-18]] ('''closed''' on October 29, 2020)
  
*[[Media:QIBA_fMRI_Profile_1_PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
+
*[[Media:QIBA fMRI Profile 1 PC-rev1.pdf| fMRI for Sensorimotor Mapping 2017-06-19]] ('''closed''' on December 31, 2017)
  
  
'''[[Comment Resolutions]]''' <font color=black>are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.<font>
+
'''[[Comment Resolutions]]''' <font color="black">are posted for '''Past Public Comments''' and '''Past Technical Confirmations'''.
  
  
Line 60: Line 62:
 
Cite QIBA Profile documents as:
 
Cite QIBA Profile documents as:
  
: ''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
+
:''Specific QIBA Biomarker Committee. Specific Profile Title'', Quantitative Imaging Biomarkers Alliance. ''Version. Profile Stage''. ''Date''. Available from: ''URL''
  
 
Example:
 
Example:
  
: QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
+
:QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles
 +
 
  
 
====Statements of Endorsement====
 
====Statements of Endorsement====
Line 71: Line 74:
 
*[[Additional letters of support can be found here]]
 
*[[Additional letters of support can be found here]]
  
====See Also====
+
 
 +
==== See Also====
 
*[[How to use QIBA Profiles]]
 
*[[How to use QIBA Profiles]]
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.
 
*[[Committees|Biomarker Committee]] pages may also have links to DRAFT Profile documents for the next Stage.

Latest revision as of 15:35, 31 August 2022

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

  • 32 pages including Conformance Checklists

Stage 2: Consensus Profiles

Stage 1: Public Comment Profiles

Please submit comments using the online form


Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.


Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Version. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles


Statements of Endorsement


See Also